Free Trial

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

$85.02
+1.11 (+1.32%)
(As of 07/12/2024 ET)

BioMarin Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$106.37
25.11% Upside
High Forecast$185.00
Average Forecast$106.37
Low Forecast$72.00
TypeCurrent Forecast
7/14/23 to 7/13/24
1 Month Ago
6/14/23 to 6/13/24
3 Months Ago
4/15/23 to 4/14/24
1 Year Ago
7/14/22 to 7/14/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
7 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$106.37$106.11$107.61$118.19
Forecasted Upside25.11% Upside25.73% Upside24.23% Upside25.36% Upside
Get BioMarin Pharmaceutical Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.

BMRN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BMRN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioMarin Pharmaceutical Stock vs. The Competition

TypeBioMarin PharmaceuticalMedical CompaniesS&P 500
Consensus Rating Score
2.57
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside25.11% Upside994.21% Upside9.17% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/27/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$110.00 ➝ $115.00+38.40%
5/17/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Allen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/17/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral$104.00 ➝ $72.00-6.46%
5/14/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$113.00+40.37%
4/26/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$115.00 ➝ $112.00+37.61%
4/26/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$91.00 ➝ $89.00+8.31%
4/25/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$94.00 ➝ $91.00+10.75%
4/25/2024Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector Perform ➝ Sector Perform$83.00 ➝ $85.00+4.58%
4/25/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$110.00+33.89%
2/23/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$115.00 ➝ $107.00+17.39%
2/23/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSector Perform ➝ Sector Perform$100.00+8.47%
12/21/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$101.00+6.47%
11/3/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$102.00 ➝ $100.00+25.52%
11/2/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$125.00 ➝ $111.00+39.32%
11/2/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$78.00-2.10%
10/23/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform$82.00-0.13%
9/28/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
9/25/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$140.00+61.83%
9/18/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$120.00+36.12%
9/13/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$110.00+19.40%
7/21/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$185.00+110.23%
6/30/2023500.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingReiterates
4/27/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
2/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$110.00 ➝ $127.00+23.01%
2/22/2023Avian Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeMarket Perform
2/22/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
2/3/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$122.00 ➝ $130.00+15.21%
11/29/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$100.00 ➝ $120.00+21.63%
10/24/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$140.00 ➝ $112.00+24.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:54 AM ET.

BMRN Forecast - Frequently Asked Questions

What is BioMarin Pharmaceutical's forecast for 2024?

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for BioMarin Pharmaceutical is $106.37, with a high forecast of $185.00 and a low forecast of $72.00.

Should I buy or sell BioMarin Pharmaceutical stock right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 9 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BMRN shares.

Does BioMarin Pharmaceutical's stock price have much upside?

According to analysts, BioMarin Pharmaceutical's stock has a predicted upside of 26.01% based on their 12-month stock forecasts.

Has BioMarin Pharmaceutical been downgraded by Wall Street analysts recently?

Over the previous 90 days, BioMarin Pharmaceutical's stock had 2 downgrades by analysts.

What analysts cover BioMarin Pharmaceutical?

BioMarin Pharmaceutical has been rated by research analysts at Baird R W, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Evercore ISI, Morgan Stanley, Robert W. Baird, Scotiabank, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like BioMarin Pharmaceutical more than its competitors?

Analysts like BioMarin Pharmaceutical less than other "medical" companies. The consensus rating score for BioMarin Pharmaceutical is 2.57 while the average consensus rating score for "medical" companies is 2.71. Learn more on how BMRN compares to other companies.


This page (NASDAQ:BMRN) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners